Evidence map›Paper›PMID 40198862›Full record

ArticleNeurology2025

Longitudinal Evolution of Posterior Cortical Atrophy: Diagnostic Delays, Overlapping Phenotypes, and Clinical Outcomes.

Dror Shir, Noah Lee, Stuart J McCarter, Vijay K Ramanan, Hugo Botha, David S Knopman, Ronald C Petersen, Bradley F Boeve, Gregory Scott Day, Neill R Graff-Radford and 10 more

Abstract read
In one paragraph

Article in Neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Dror ShirDepartment of Neurology, Mayo Clinic, Rochester, MN.ORCID 0000-0003-2811-3421
Noah LeeMayo Clinic Alix School of Medicine, Rochester, MN.ORCID 0009-0001-4944-3764
Stuart J McCarterDepartment of Neurology, Mayo Clinic, Rochester, MN.ORCID 0000-0001-8158-8835
Vijay K RamananDepartment of Neurology, Mayo Clinic, Rochester, MN.ORCID 0000-0001-6591-8734
Hugo BothaDepartment of Neurology, Mayo Clinic, Rochester, MN.ORCID 0000-0003-4390-685X
David S KnopmanDepartment of Neurology, Mayo Clinic, Rochester, MN.ORCID 0000-0002-6544-066X
Ronald C PetersenDepartment of Neurology, Mayo Clinic, Rochester, MN.ORCID 0000-0002-8178-6601
Bradley F BoeveDepartment of Neurology, Mayo Clinic, Rochester, MN.ORCID 0000-0002-4153-8187
Gregory Scott DayDepartment of Neurology, Mayo Clinic, Jacksonville, FL.ORCID 0000-0001-5133-5538
Neill R Graff-RadfordDepartment of Neurology, Mayo Clinic, Jacksonville, FL.ORCID 0000-0001-9847-9096
David T JonesDepartment of Neurology, Mayo Clinic, Rochester, MN.ORCID 0000-0002-4807-9833
Melissa E MurrayDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL.ORCID 0000-0001-7379-2545
Aivi T NguyenDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.ORCID 0000-0003-1809-9451
R Ross ReichardDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.ORCID 0000-0003-0842-2462
Dennis W DicksonDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL.ORCID 0000-0001-7189-7917
Deena TajfirouzDepartment of Neurology, Mayo Clinic, Rochester, MN.ORCID 0000-0001-8419-8728
Mary M MachuldaDepartment of Psychiatry and Psychology, Mayo Clinic, Rochester, MN; and.ORCID 0000-0003-4834-5967
Jennifer L WhitwellDepartment of Radiology, Mayo Clinic, Rochester, MN.ORCID 0000-0001-6914-1563
Keith Anthony JosephsDepartment of Neurology, Mayo Clinic, Rochester, MN.ORCID 0000-0003-2930-8634
Jonathan Graff-RadfordDepartment of Neurology, Mayo Clinic, Rochester, MN.ORCID 0000-0003-2770-0691

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesAlthough several large studies have evaluated individuals with posterior cortical atrophy (PCA) cross-sectionally, its longitudinal progression remains poorly characterized. The objectives of this study were to determine the longitudinal trajectory of PCA, encompassing the temporal aspects of diagnosis, the spectrum of clinical manifestations, and patient outcomes.

methodsThis retrospective study included participants evaluated and diagnosed with PCA at the Mayo Clinic, between 1995 and 2023. Clinical data (demographics, neurologic evaluations, and cognitive tests at initial presentation and late stage) were extracted from medical records. Initial clinical diagnoses during previous medical evaluations, including ophthalmologic assessments after onset of neurologic symptoms, were documented. Participants were retrospectively classified as PCA-pure if they solely met PCA criteria or as PCA-plus if they exhibited complex phenotypes also meeting criteria for other neurodegenerative syndromes. CSF analyses and neuropathology findings were documented.

resultsThe cohort of 558 participants (65% female) had a mean age at symptom onset of 61 ± 8 years, with 68% meeting early-onset criteria (younger than 65 years). The mean duration from symptom onset to diagnosis was 3.6 ± 2.5 years. Ophthalmologic/optometric evaluations (49%) and completion of ophthalmologic procedures (16%) were common before PCA diagnosis. Psychiatric diagnoses were made in 23% of participants before PCA diagnosis, particularly among younger women. Common initial symptoms included misplacement of items, difficulties with reading and driving, and concerns pertaining to basic visual processing. Notable signs were constructional apraxia, dyscalculia, simultanagnosia, and space perception deficits. CSF biomarkers were consistent with Alzheimer disease in 139 of 158 individuals (88%). Superimposed features of non-PCA clinical syndromes were observed in a quarter of the participants at presentation, with frequency of PCA-plus cases increasing longitudinally. Longitudinal analysis of Short Test of Mental Status scores predicted an initial rapid decline in cognitive function, with the rate of decline gradually slowing over 0-10 years (time coefficient [SE] = -4.20 [0.29], DISCUSSION: This study highlights the protracted time from symptom onset and frequent misdiagnoses/misattribution of symptoms in PCA. Ophthalmologic evaluations often preceded neurologic assessments. Psychiatric diagnoses were more frequent among younger women. These observations highlight the need to improve diagnostic processes and earlier recognition of PCA, which may enhance the effectiveness of emerging disease-modifying therapies.

Indexed as

Cerebral CortexDelayed DiagnosisNeurodegenerative DiseasesAgedAtrophyDisease ProgressionFemaleHumansLongitudinal StudiesMaleMiddle AgedPhenotypeRetrospective Studies

Identifiers

PMID40198862
PMCPMC11984831

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.